BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elenestinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Elenestinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04910685-11344@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Elenestinib: Phase 2/3 readout est. (NCT04910685)
DESCRIPTION:Elenestinib\, phase 2/3\, Systemic Mastocytosis.\nStudy: (HARBO
 R) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Pati
 ents With Indolent Systemic Mastocytosis\nEstimated primary completion: 30
  September 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elen
 estinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04910685
URL:https://assetmemo.bio/drug/elenestinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
